Bristol-Myers Squibb BMY
-
Citi upgrades Bristol-Myers Squibb ( BMY ) to Buy from Neutral and raises its price target to $55 from $33 saying the company's "very broad checkpoint agent [is] positioned to capture a very ...
Citi upgrades Bristol - Myers Squibb ( BMY ) to Buy from Neutral and raises its price target to $55 from $33 saying the company's "very broad checkpoint agent [is …
-
Amicus Therapeutics' CEO Presents at 2013 UBS Global Healthcare Conference (Transcript)
… Novazyme before its acquisition of Genzyme, prior to Amicus. He also has experience as a naval officer and at Bristol - Myers Squibb . But he is probably most well-known for his personal drive to find solutions for rare diseases. Following the …
-
Bristol-Myers Squibb's Management Presents at UBS Global Healthcare Services Conference (Transcript)
Bristol - Myers Squibb Company ( BMY ) UBS Global Healthcare Services ..... We are lucky enough to have Bristol - Myers with us; we have Charlie Bancroft ..... seekingalpha.com/article/1450951- bristol - myers - squibb -s-management-presents-at-ubs-global-healthcare-services-conference-transcript …
-
Bristol Myers Squibb And The New Wave Of Cancer Drugs
… one course of treatment. Bristol 's Nivolumab Bristol - Myers Squibb ( BMY ) is the frontrunner in the race. Bristol 's nivolumab, at the center ..... combination of two drugs from Bristol - Myers Squibb shrank tumors significantly …
-
Bristol - Myers , Merck And Roche: R&D Finds Golden Pill, So Buy
… Street Journal wrote, " Cancer Drugs' New Weapon ." Based on "immunotherapy," each of the R&D departments at Bristol - Myers ( BMY ), Merck ( MRK ) and Roche ( RHHBF.PK ) are creating new cancer-fighting drugs. What makes the news exciting …
-
Theravance's CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)
… that’s been flowing through this story in recent weeks. Just a quick comment on Rick, Rick cut his teeth at Bristol - Myers . He had a very successful career there, 15 years, and he has been at Theravance for a dozen years, and he is here …
-
Bristol melanoma drug combo marks new advance in immunotherapy
CHICAGO, May 15 (Reuters) - Melanoma patients treated with two Bristol - Myers Squibb drugs fared much better than those who received either of the medications individually, a new advance for...
-
Bristol - Myers shares jump ahead of melanoma trial data
CHICAGO/NEW YORK (Reuters) - Shares of drugmaker Bristol - Myers Squibb Co rose to a 10-year high on Wednesday ahead of results of an early stage trial for its new melanoma treatment, with heavy...
-
UPDATE 1- Bristol - Myers shares jump ahead of melanoma trial data
CHICAGO/NEW YORK, May 15 (Reuters) - Shares of drugmaker Bristol - Myers Squibb Co rose to a 10-year high on Wednesday ahead of results of an early stage trial for its new melanoma treatment, with...
-
Bristol - Myers shares jump ahead of melanoma trial data
CHICAGO/NEW YORK, May 15 (Reuters) - Shares of drugmaker Bristol - Myers Squibb Co rose to a ten-year high on Wednesday ahead of results of an early stage trial for its new melanoma treatment, with...